Amendments

In the Claims:

Please cancel claims 49 and 51-53 without prejudice or disclaimer and amend the remaining claims to read as follows:

37. **(Twice Amended)** A pharmaceutical kit comprising:

(a) a first component comprising a bifunctional fusion glycoprotein or conjugate thereof comprising

(i) at least one first portion which is an enzyme selected from the group consisting of penicillin G amidase, penicillin V amidase, β-lactamase, alkaline phosphatase, carboxypeptidase G2, carboxypeptidase A, cytosine deaminase, nitroreductase, diaphorase, arylsulfatase, glycosidase, β-glucosidase, and β-glucuronidase; and

(ii) at least one second portion which comprises a monoclonal antibody BW 431/26 or an antigen binding fragment thereof that binds said first component to a tumor-specific antigen on a tumor cell;

wherein said fusion glycoprotein or conjugate thereof comprises at least one carbohydrate complement comprising at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, lactose, N-acetyllactose, glucose and fucose; and

(b) a second component comprising a non-toxic prodrug that is subsequently cleaved into a tumor cytotoxic drug by said enzymatic activity of said first component,

wherein each of said first and said second components is in a pharmaceutically acceptable vehicle.

54. **(Amended)** A kit as claimed in claim 37, wherein said fusion glycoprotein or conjugate thereof is synthesized in hosts selected from the group consisting of mammalian cells, microorganisms, insect cells and transgenic animals.

58. **(Twice Amended)** A method of treating a tumor in a subject, comprising:

(a) administering to said subject in a first step, a first component comprising a bifunctional fusion glycoprotein or conjugate thereof comprising

(i) at least one first portion which is an enzyme selected from the group consisting of penicillin G amidase, penicillin V amidase, β-lactamase, alkaline phosphatase, carboxypeptidase G2, carboxypeptidase A, cytosine deaminase, nitroreductase, diaphorase, arylsulfatase, glycosidase, β-glucosidase, and β-glucuronidase; and

(ii) at least one second portion which comprises a monoclonal antibody BW 431/26 or an antigen binding fragment thereof that binds said first component to a tumor-specific antigen on a tumor cell;

wherein said fusion glycoprotein or conjugate thereof comprises at least one carbohydrate complement comprising at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, lactose, N-acetyllactose, glucose and fucose; and

(b) administering to said subject in a second step, a second component comprising a non-toxic prodrug that is subsequently cleaved into a tumor cytotoxic drug by said enzymatic activity of said first component,

wherein each of said first and said second components is in a pharmaceutically acceptable vehicle.

Please add the following new claims:

-- 66. **(New)** A pharmaceutical kit comprising:

(a) a first component comprising a bifunctional fusion glycoprotein or conjugate thereof of the formula huTuMab-L-β-Gluc, wherein huTuMab is a human tumor specific monoclonal antibody or an antigen binding fragment thereof, L is said linker molecule, and β-Gluc is a human β-glucuronidase;

wherein said glycoprotein or conjugate thereof comprises at least one carbohydrate complement comprising at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, lactose, N-acetyllactose, glucose and fucose; and

(b) a second component comprising a non-toxic prodrug that is subsequently cleaved into a tumor cytotoxic drug by said enzymatic activity of said first component.

67. **(New)** A method of treating a tumor in a subject, comprising:

(a) administering to said subject in a first step, a first component comprising a first component comprising a bifunctional fusion glycoprotein or conjugate thereof of the formula huTuMab-L-β-Gluc, wherein huTuMab is a human tumor specific monoclonal antibody or an antigen binding fragment thereof, L is said linker molecule, and β-Gluc is a human β-glucuronidase;

wherein said glycoprotein or conjugate thereof comprises at least one carbohydrate complement comprising at least one exposed carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, lactose, N-acetyllactose, glucose and fucose; and

(b) administering to said subject in a second step, a second component comprising a non-toxic prodrug that is subsequently cleaved into a tumor cytotoxic drug by said enzymatic activity of said first component.